Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference
Published: Dec 28, 2012
CAMBRIDGE, MA--(Marketwire - December 28, 2012) - Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2013 31st Annual JP Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 4:30pm Pacific Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarepta Therapeutics' website at www.sareptatherapeutics.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Sarepta Media and Investor Contact: